{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:19Z","timestamp":1792788079337,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The State of Nebraska","award":["CHRI-PCRG Grant Funds (LB905)"],"award-info":[{"award-number":["CHRI-PCRG Grant Funds (LB905)"]}]},{"name":"The Team Jack Foundation","award":["Power 5 Grant"],"award-info":[{"award-number":["Power 5 Grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Medulloblastoma (MB) patients with MYC oncogene amplification or overexpression exhibit extremely poor prognoses and therapy resistance. However, MYC itself has been one of the most challenging targets for cancer treatment. Here, we identify a novel marinopyrrole natural derivative, MP1, that shows desirable anti-MYC and anti-cancer activities in MB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, using MYC-amplified (Group 3) and non-MYC amplified MB cell lines in vitro and in vivo, we evaluated anti-cancer efficacies and molecular mechanism(s) of MP1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MP1 significantly suppressed MB cell growth and sphere counts and induced G2 cell cycle arrest and apoptosis in a MYC-dependent manner. Mechanistically, MP1 strongly downregulated the expression of MYC protein. Our results with RNA-seq revealed that MP1 significantly modulated global gene expression and inhibited MYC-associated transcriptional targets including translation\/mTOR targets. In addition, MP1 inhibited MYC-target metabolism, leading to declined energy levels. The combination of MP1 with an FDA-approved mTOR inhibitor temsirolimus synergistically inhibited MB cell growth\/survival by downregulating the expression of MYC and mTOR signaling components. Our results further showed that as single agents, both MP1 and temsirolimus, were able to significantly inhibit tumor growth and MYC expression in subcutaneously or orthotopically MYC-amplified MB bearing mice. In combination, there were further anti-MB effects on the tumor growth and MYC expression in mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These preclinical findings highlight the promise of marinopyrrole MP1 as a novel MYC inhibition approach for MYC-amplified MB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-024-02944-w","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T22:02:36Z","timestamp":1704924156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma"],"prefix":"10.1186","volume":"43","author":[{"given":"Don W.","family":"Coulter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashpal S.","family":"Chhonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Kesherwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafaa N.","family":"Aldhafiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gracey","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutapa","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantaram S.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongshi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Murry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7037-898X","authenticated-orcid":false,"given":"Nagendra K.","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"2944_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017. Neuro Oncol. 2020;22:iv1\u201396.","journal-title":"Neuro Oncol"},{"key":"2944_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.14791\/btrt.2022.0046","volume":"11","author":"JY Choi","year":"2023","unstructured":"Choi JY. Medulloblastoma: current perspectives and recent Advances. Brain Tumor Res Treat. 2023;11:28\u201338.","journal-title":"Brain Tumor Res Treat"},{"key":"2944_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","volume":"123","author":"MD Taylor","year":"2012","unstructured":"Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123:465\u201372.","journal-title":"Acta Neuropathol"},{"issue":"737\u2013754","key":"2944_CR4","first-page":"e736","volume":"31","author":"FMG Cavalli","year":"2017","unstructured":"Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, et al. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017;31(737\u2013754):e736.","journal-title":"Cancer Cell"},{"key":"2944_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nature22973","volume":"547","author":"PA Northcott","year":"2017","unstructured":"Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, Grobner S, Segura-Wang M, Zichner T, Rudneva VA, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017;547:311\u20137.","journal-title":"Nature"},{"key":"2944_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41568-019-0223-8","volume":"20","author":"V Hovestadt","year":"2020","unstructured":"Hovestadt V, Ayrault O, Swartling FJ, Robinson GW, Pfister SM, Northcott PA. Medulloblastomics revisited: biological and clinical insights from thousands of patients. Nat Rev Cancer. 2020;20:42\u201356.","journal-title":"Nat Rev Cancer"},{"key":"2944_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231\u201351.","journal-title":"Neuro Oncol"},{"key":"2944_CR8","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1200\/JCO.2010.28.5148","volume":"29","author":"YJ Cho","year":"2011","unstructured":"Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29:1424\u201330.","journal-title":"J Clin Oncol"},{"key":"2944_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/diagnostics12010061","volume":"12","author":"S Ray","year":"2021","unstructured":"Ray S, Chaturvedi NK, Bhakat KK, Rizzino A, Mahapatra S. Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment. Diagnostics (Basel). 2021;12:61.","journal-title":"Diagnostics (Basel)"},{"key":"2944_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"YT Lee","year":"2018","unstructured":"Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188\u201396.","journal-title":"Eur J Pharmacol"},{"key":"2944_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","volume":"3","author":"H Chen","year":"2018","unstructured":"Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3:5.","journal-title":"Signal Transduct Target Ther"},{"key":"2944_CR12","doi-asserted-by":"publisher","first-page":"103756","DOI":"10.1016\/j.ebiom.2021.103756","volume":"75","author":"V Llombart","year":"2022","unstructured":"Llombart V, Mansour MR. Therapeutic targeting of \u201cundruggable\u201d MYC. EBioMedicine. 2022;75:103756.","journal-title":"EBioMedicine"},{"key":"2944_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/med.21359","volume":"36","author":"R Li","year":"2016","unstructured":"Li R. Marinopyrroles: unique drug discoveries based on marine natural products. Med Res Rev. 2016;36:169\u201389.","journal-title":"Med Res Rev"},{"key":"2944_CR14","doi-asserted-by":"publisher","first-page":"10224","DOI":"10.1074\/jbc.M111.334532","volume":"287","author":"K Doi","year":"2012","unstructured":"Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, Krishnegowda G, Awwad A, Dewey A, Liu X, et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem. 2012;287:10224\u201335.","journal-title":"J Biol Chem"},{"key":"2944_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ejmech.2014.11.035","volume":"90","author":"R Li","year":"2015","unstructured":"Li R, Cheng C, Balasis ME, Liu Y, Garner TP, Daniel KG, Li J, Qin Y, Gavathiotis E, Sebti SM. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1\/Bcl-xL inhibitors. Eur J Med Chem. 2015;90:315\u201331.","journal-title":"Eur J Med Chem"},{"key":"2944_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ejmech.2016.08.017","volume":"124","author":"Z Yang","year":"2016","unstructured":"Yang Z, Liu Y, Ahn J, Qiao Z, Endres JL, Gautam N, Huang Y, Li J, Zheng J, Alnouti Y, et al. Novel fluorinated pyrrolomycins as potent anti-staphylococcal biofilm agents: Design, synthesis, pharmacokinetics and antibacterial activities. Eur J Med Chem. 2016;124:129\u201337.","journal-title":"Eur J Med Chem"},{"key":"2944_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1021\/cc100052j","volume":"12","author":"C Cheng","year":"2010","unstructured":"Cheng C, Pan L, Chen Y, Song H, Qin Y, Li R. Total synthesis of (+\/-)-marinopyrrole A and its library as potential antibiotic and anticancer agents. J Comb Chem. 2010;12:541\u20137.","journal-title":"J Comb Chem"},{"key":"2944_CR18","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.3390\/md12052458","volume":"12","author":"Y Liu","year":"2014","unstructured":"Liu Y, Haste NM, Thienphrapa W, Li J, Nizet V, Hensler M, Li R. Marinopyrrole derivatives as potential antibiotic agents against methicillin-resistant Staphylococcus aureus (III). Mar Drugs. 2014;12:2458\u201370.","journal-title":"Mar Drugs"},{"key":"2944_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1186\/s12885-019-6033-2","volume":"19","author":"TR McGuire","year":"2019","unstructured":"McGuire TR, Coulter DW, Bai D, Sughroue JA, Li J, Yang Z, Qiao Z, Liu Y, Murry DJ, Chhonker YS, et al. Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus. BMC Cancer. 2019;19:837.","journal-title":"BMC Cancer"},{"key":"2944_CR20","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.3390\/molecules25245898","volume":"25","author":"WN Aldhafiri","year":"2020","unstructured":"Aldhafiri WN, Chhonker YS, Zhang Y, Coutler DW, McGuire TR, Li R, Murry DJ. Assessment of Tissue Distribution and Metabolism of MP1, a Novel Pyrrolomycin, in Mice Using a Validated LC-MS\/MS Method. Molecules. 2020;25:5898.","journal-title":"Molecules"},{"key":"2944_CR21","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1158\/1535-7163.MCT-13-0239","volume":"12","author":"NK Chaturvedi","year":"2013","unstructured":"Chaturvedi NK, Rajule RN, Shukla A, Radhakrishnan P, Todd GL, Natarajan A, Vose JM, Joshi SS. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-kappaB and mTOR dual-targeting approach. Mol Cancer Ther. 2013;12:2006\u201317.","journal-title":"Mol Cancer Ther"},{"key":"2944_CR22","doi-asserted-by":"publisher","first-page":"16619","DOI":"10.18632\/oncotarget.24618","volume":"9","author":"NK Chaturvedi","year":"2018","unstructured":"Chaturvedi NK, Kling MJ, Coulter DW, McGuire TR, Ray S, Kesherwani V, Joshi SS, Sharp JG. Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy. Oncotarget. 2018;9:16619\u201333.","journal-title":"Oncotarget"},{"key":"2944_CR23","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1158\/1535-7163.MCT-19-0996","volume":"19","author":"NK Chaturvedi","year":"2020","unstructured":"Chaturvedi NK, Kling MJ, Griggs CN, Kesherwani V, Shukla M, McIntyre EM, Ray S, Liu Y, McGuire TR, Sharp JG, et al. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma. Mol Cancer Ther. 2020;19:1351\u201362.","journal-title":"Mol Cancer Ther"},{"key":"2944_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ddr.22012","volume":"84","author":"SL Haney","year":"2023","unstructured":"Haney SL, Feng D, Chhonker YS, Varney ML, Williams JT, Smith LM, Ford JB, Murry DJ, Holstein SA. Evaluation of geranylgeranyl diphosphate synthase inhibition as a novel strategy for the treatment of osteosarcoma and Ewing sarcoma. Drug Dev Res. 2023;84:62\u201374.","journal-title":"Drug Dev Res"},{"key":"2944_CR25","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41591-018-0207-3","volume":"24","author":"S Brabetz","year":"2018","unstructured":"Brabetz S, Leary SES, Grobner SN, Nakamoto MW, Seker-Cin H, Girard EJ, Cole B, Strand AD, Bloom KL, Hovestadt V, et al. A biobank of patient-derived pediatric brain tumor models. Nat Med. 2018;24:1752\u201361.","journal-title":"Nat Med"},{"key":"2944_CR26","doi-asserted-by":"publisher","first-page":"a014308","DOI":"10.1101\/cshperspect.a014308","volume":"3","author":"MF Roussel","year":"2013","unstructured":"Roussel MF, Robinson GW. Role of MYC in Medulloblastoma. Cold Spring Harb Perspect Med. 2013;3:a014308.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2944_CR27","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1093\/neuonc\/nor022","volume":"13","author":"A Raso","year":"2011","unstructured":"Raso A, Mascelli S, Biassoni R, Nozza P, Kool M, Pistorio A, Ugolotti E, Milanaccio C, Pignatelli S, Ferraro M, et al. High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma. Neuro Oncol. 2011;13:500\u20138.","journal-title":"Neuro Oncol"},{"key":"2944_CR28","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-09-1970","volume":"69","author":"D Ruggero","year":"2009","unstructured":"Ruggero D. The role of Myc-induced protein synthesis in cancer. Cancer Res. 2009;69:8839\u201343.","journal-title":"Cancer Res"},{"key":"2944_CR29","doi-asserted-by":"publisher","first-page":"11988","DOI":"10.1073\/pnas.1310230110","volume":"110","author":"M Pourdehnad","year":"2013","unstructured":"Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A. 2013;110:11988\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2944_CR30","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","volume":"5","author":"ZE Stine","year":"2015","unstructured":"Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, Metabolism, and Cancer. Cancer Discov. 2015;5:1024\u201339.","journal-title":"Cancer Discov"},{"key":"2944_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.gde.2017.10.011","volume":"48","author":"S Biffo","year":"2018","unstructured":"Biffo S, Manfrini N, Ricciardi S. Crosstalks between translation and metabolism in cancer. Curr Opin Genet Dev. 2018;48:75\u201381.","journal-title":"Curr Opin Genet Dev"},{"key":"2944_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-020-00235-2","volume":"5","author":"Y Dong","year":"2020","unstructured":"Dong Y, Tu R, Liu H, Qing G. Regulation of cancer cell metabolism: oncogenic MYC in the driver\u2019s seat. Signal Transduct Target Ther. 2020;5:124.","journal-title":"Signal Transduct Target Ther"},{"key":"2944_CR33","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"2944_CR34","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.4161\/cc.20008","volume":"11","author":"WL Labisso","year":"2012","unstructured":"Labisso WL, Wirth M, Stojanovic N, Stauber RH, Schnieke A, Schmid RM, Kramer OH, Saur D, Schneider G. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle. 2012;11:1593\u2013602.","journal-title":"Cell Cycle"},{"key":"2944_CR35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cmet.2017.09.009","volume":"26","author":"KM Lee","year":"2017","unstructured":"Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, Nixon MJ, Estrada MV, Sanchez V, Sanders ME, et al. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metab. 2017;26:633-647 e637.","journal-title":"Cell Metab"},{"key":"2944_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41419-020-02760-y","volume":"11","author":"X Wu","year":"2020","unstructured":"Wu X, Luo Q, Liu Z. Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options. Cell Death Dis. 2020;11:556.","journal-title":"Cell Death Dis"},{"key":"2944_CR37","doi-asserted-by":"publisher","first-page":"1007641","DOI":"10.3389\/fcell.2022.1007641","volume":"10","author":"V Marabitti","year":"2022","unstructured":"Marabitti V, Giansanti M, De Mitri F, Gatto F, Mastronuzzi A, Nazio F. Pathological implications of metabolic reprogramming and its therapeutic potential in medulloblastoma. Front Cell Dev Biol. 2022;10:1007641.","journal-title":"Front Cell Dev Biol"},{"key":"2944_CR38","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1186\/s12885-019-6291-z","volume":"19","author":"NK Chaturvedi","year":"2019","unstructured":"Chaturvedi NK, Mahapatra S, Kesherwani V, Kling MJ, Shukla M, Ray S, Kanchan R, Perumal N, McGuire TR, Sharp JG, et al. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma. BMC Cancer. 2019;19:1056.","journal-title":"BMC Cancer"},{"key":"2944_CR39","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nn1473","volume":"8","author":"A Lee","year":"2005","unstructured":"Lee A, Kessler JD, Read TA, Kaiser C, Corbeil D, Huttner WB, Johnson JE, Wechsler-Reya RJ. Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci. 2005;8:723\u20139.","journal-title":"Nat Neurosci"},{"key":"2944_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ccr.2011.12.021","volume":"21","author":"Y Pei","year":"2012","unstructured":"Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell. 2012;21:155\u201367.","journal-title":"Cancer Cell"},{"key":"2944_CR41","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/onc.2016.235","volume":"36","author":"N Garg","year":"2017","unstructured":"Garg N, Bakhshinyan D, Venugopal C, Mahendram S, Rosa DA, Vijayakumar T, Manoranjan B, Hallett R, McFarlane N, Delaney KH, et al. CD133(+) brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence. Oncogene. 2017;36:606\u201317.","journal-title":"Oncogene"},{"key":"2944_CR42","doi-asserted-by":"publisher","first-page":"659055","DOI":"10.3389\/fcell.2021.659055","volume":"9","author":"RN Curry","year":"2021","unstructured":"Curry RN, Glasgow SM. The role of neurodevelopmental pathways in brain tumors. Front Cell Dev Biol. 2021;9:659055.","journal-title":"Front Cell Dev Biol"},{"key":"2944_CR43","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","volume":"101","author":"A Szwed","year":"2021","unstructured":"Szwed A, Kim E, Jacinto E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev. 2021;101:1371\u2013426.","journal-title":"Physiol Rev"},{"key":"2944_CR44","doi-asserted-by":"publisher","first-page":"8748","DOI":"10.1158\/0008-5472.CAN-10-0944","volume":"70","author":"KR Luoto","year":"2010","unstructured":"Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ, Bristow RG. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res. 2010;70:8748\u201359.","journal-title":"Cancer Res"},{"key":"2944_CR45","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.3892\/or.2020.7806","volume":"44","author":"Y Fan","year":"2020","unstructured":"Fan Y, Jia X, Xie T, Zhu L, He F. Radiosensitizing effects of c-myc gene knockdown-induced G2\/M phase arrest by intrinsic stimuli via the mitochondrial signaling pathway. Oncol Rep. 2020;44:2669\u201377.","journal-title":"Oncol Rep"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-02944-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-02944-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-02944-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T23:44:57Z","timestamp":1704930297000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-02944-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2944"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-02944-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"assertion":[{"value":"14 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed according to a UNMC Institutional Animal Care and Use Committee (IACUC) approved protocol, #18\u2013037-06-FC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication:"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}